Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

BACKGROUND: Psoriasis causes work productivity impairment that increases with disease severity. Whether differential treatment efficacy translates into differential indirect cost savings is unknown. OBJECTIVE: To assess work hours lost and indirect costs associated with secukinumab versus ustekinuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, R.B., Halliday, A., Graham, C.N., Gilloteau, I., Miles, L., McBride, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586050/
https://www.ncbi.nlm.nih.gov/pubmed/29846965
http://dx.doi.org/10.1111/jdv.15094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586050/
https://www.ncbi.nlm.nih.gov/pubmed/29846965
http://dx.doi.org/10.1111/jdv.15094

Ejemplares similares